Home
About +
Our Story
Meet the Team
FAQs
Our Science +
Inhaled IFN-β
Clinical Trials
Publications
Investors +
Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
Investor Calendar
News +
Press Releases
Resources
Factsheets
TR-1/Options Press Releases
Careers
Contact
Home
About
Our Science
Investors
News
Careers
Contact
Back
Our Story
Meet the Team
FAQs
Back
Inhaled IFN-β
Clinical Trials
Publications
Back
Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
Investor Calendar
Back
Press Releases
Resources
Factsheets
TR-1/Options Press Releases
Media
Read our latest news and download information and resources.
Featured News
Martin Murphy appointed as Non-Executive Director
Result of General Meeting and Total Voting Rights
£18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections
In the News
Discover all mentions
Read our CEO Richard Marsden's 2023 Letter
The Need - and Opportunity - to Develop Broad-Spectrum Antivirals by Dr Phillip Monk
ITN Lungs Matter
Press
View all press releases
Subscribe to news
2025
Martin Murphy appointed as Non-Executive Director
16th January 2025
Result of General Meeting and Total Voting Rights
16th January 2025
£18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections
15th January 2025
2024
Proposed Fundraising to raise a minimum of £18 million and a maximum of £19 million
20th December 2024
Results of AGM and Appointment of New Chairman
10th October 2024
Interim Results
26th September 2024
Appointment of New Chairman and Notice of AGM
18th September 2024
Board Change
5th September 2024
Results for the year ended 31 December 2023
27th June 2024
2023
Appointment of Joseph Colliver as New Chief Financial Officer
11th October 2023
